Home > Rheumatology > EULAR 2019 > Miscellaneous > Support for Tocilizumab Use in Giant Cell Arteritis

Support for Tocilizumab Use in Giant Cell Arteritis

Presented By
Dr John Stone, Massachusetts General Hospital, Boston, USA
Conference
EULAR 2019
Trial
GiACTA

A significant proportion of patients with giant cell arteritis (GCA) remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years. This was demonstrated in a follow-up study from the double-blind, randomised GiACTA trial [1]. Additionally, restarting tocilizumab restores clinical remission among those patients who do experience disease flare. No new safety signals were observed.

In patients with GCA, the use of the interleukin-6 receptor inhibitor tocilizumab in combination with 26-week prednisone tapering resulted in higher rates of sustained glucocorticoid-free remission compared with placebo and prednisone tapering in week 52 of the GiACTA trial [2]. Dr John Stone (Massachusetts General Hospital, Boston, USA) et al. aimed to investigate longer-term efficacy and safety of tocilizumab in GCA patients in this 2-year long-term extension of the GiACTA trial.

Patients in clinical remission (n=127) at t...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on